drugset / Trial / NCT00432679

A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study

NCT00432679

Phase 3 Completed 149 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This study was designed to compare the efficacy and safety of BRL49653C versus placebo with concomitant use of sulfonyl urea (SU).

Timeline

Start
2006-05-24
Primary completion
2007-03-28
Completion
2007-03-28

Publications

  • Background This study has not been published in the scientific literature.

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosiglitazone Small molecule